Kevin M. Kalinsky, MD, reflects on a meaningful experience with a patient with metastatic breast cancer that is HER2-low.
Dr Kalinsky details how the recently approved antibody-drug conjugate trastuzumab deruxtecan produced a positive response, which gave him a tremendous sense of gratification.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: An Impactful Experience With a Patient With Metastatic Breast Cancer - Medscape - Jan 06, 2023.